January 30, 2014 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that the company will make personnel changes.
Effective March 27, 2014
Board Members
Name
New Responsibilities
Old Responsibilities
Yutaka Tanaka
Director, Executive Vice President
Head of Project & Lifecycle Management Unit
In charge of Research,
Clinical Development and
Medical Affairs
Senior Vice President
Head of Project & Lifecycle Management Unit
In charge of Research,
Clinical Development and
Medical Affairs
Franz B. Humer
Director
- The appointment of Yutaka Tanaka as a Director, Executive Vice President is subject to approval at the 103rd Annual General Meeting of Shareholders, which is scheduled to be convened on March 27, 2014.
- The appointment of Franz B. Humer as a Director is subject to approval at the 103rd Annual General Meeting of Shareholders, which is scheduled to be convened on March 27, 2014.
- Tatsumi Yamazaki (currently Director, Deputy President) is scheduled to retire from the Director, Deputy President and is going to take the role of Distinguished Advisor as of March 27, 2014.
- William M. Burns (currently Director) is scheduled to retire from the Director as of March 27, 2014.
Effective April 1, 2014
Executive Officers
Name
New Responsibilities
Old Responsibilities
Shinya Unno
Senior Vice President
General Manager of Corporate Planning Dept.
In charge of Human Resources
Supervisory Div., General Affairs, Secretarial and Legal
Senior Vice President
General Manager of Corporate Planning Dept.
In charge of Human Resources
Supervisory Div., General Affairs and Secretarial
Junichi Ebihara
Vice President
General Manager of Legal Dept.
Full-time Senior Advisor
- Naotaka Nakamura (currently Executive Vice President ) and Fumihiko Kamoshida (currently Senior Vice President) are scheduled to retire from the Executive Vice President and the Senior Vice President respectively, as of March 31, 2014.
- Junichi Ebihara is going to take the role of Full-time Senior Advisor as of February 1, 2014.
Please see the PDF file about other personnel changes.
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).
CHUGAI PHARMACEUTICAL CO., LTD 
By 
